Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy. However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of Siglec15 in bladder cancer (BLCA) remains elusive. Methods: We comprehensively evaluated the expression pattern and immunologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiao, Yu, Anze, Othmane, Belaydi, Qiu, Dongxu, Li, Huihuang, Li, Chao, Liu, Peihua, Ren, Wenbiao, Chen, Minfeng, Gong, Guanghui, Guo, Xi, Zhang, Huihui, Chen, Jinbo, Zu, Xiongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847675/
https://www.ncbi.nlm.nih.gov/pubmed/33537076
http://dx.doi.org/10.7150/thno.53649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847675/
https://www.ncbi.nlm.nih.gov/pubmed/33537076
http://dx.doi.org/10.7150/thno.53649

Ejemplares similares